Ph+ acute lymphoblastic leukemia
Conditions
Interventions
Case series:All patients who met the criteria were treated with the Dashatinib combined bone marrow transplantation pretreatment program to monitor the BCR-ABL fusion gene quantification before and af
Sponsors
Affiliated Hospital of Dalian Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Selection criteria: Patients must meet all of the following criteria in order to enter the study: 1. Aged from 18 to 60 years; 2. Persons who have voluntarily signed an informed consent form and are able to comply with the research program; 3. HLA full or semi-combined donor, no transplant taboo for medical examination, voluntary donation of hematopoietic stem cells; 4. Blood creatinine; 5. Persons who are not allergic to TKI.
Exclusion criteria
Exclusion criteria: 1. The combination of severe cardiopulmonary liver and kidney diseases; 2. Specific allergies and intolerance to treatment drugs; 3. Persons with a history of mental illness; 4. Persons suspected of or having a history of alcohol or substance abuse; 5. Serious or uncontrollable infections; 6. Participation in other clinical trials within the last 4 weeks; 7. The absence of regular follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCR-ABL fusion gene quantification; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ph chromosome; | — |
Countries
China
Contacts
Public ContactYan Jinsong
Affiliated second Hospital of Dalian Medical University
Outcome results
None listed